Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 , an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration 02 April
European Commission Approves KEYTRUDA® Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens 02 April
